News Reader
05-07-2009, 04:12 PM
The U.S. Food and Drug Administration announced today that it has approved Creon (pancrelipase), a pancreatic enzyme replacement product designed to help patients with cystic fibrosis and others with exocrine pancreatic insufficiency (EPI) digest and absorb nutrients from foods. Creon is the first FDA-approved delayed-release pancreatic enzyme replacement product to be marketed in the United States as a result of the agency’s unapproved drugs initiative.
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW02010.html)
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW02010.html)